Opinion|Videos|June 25, 2024
Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL
Bita Fakhri, MD, MPH, outlines factors she considers when choosing between fixed-duration and continuous BTK inhibitor therapy and discusses how she approaches treatment discussions with patients.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What factors do you consider when choosing between fixed-duration and continuous BTK inhibitor therapy?
- How do you weigh the pros and cons of each approach, including treatment logistics and time off therapy?
- How do you weigh the pros and cons of each approach, including treatment logistics and time off therapy?
Advertisement
Related to this article
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
5